TrialsgrambetaRCTs are beautiful

REDUCE-AMI

2024

Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction

In 5,020 patients after acute MI with preserved LVEF (≥50%), beta-blocker therapy did not reduce all-cause death or new MI compared with no beta-blocker.

Result

Efficacy: Death from any cause or new myocardial infarctionHR 0.96 (95% CI 0.79-1.16) · P = 0.64

Below 1 favours beta-blocker therapy, above 1 favours no beta-blocker.

Event rates
Absolute difference
0.4 points

The absolute difference is derived from the event rates.

Also reported: Neutral over median ~3.5 years in post-MI patients with LVEF ≥50%.

Original publication
Subtopic
beta-blocker
Design
Registry-based open-label RCT
Relevance
Important: one of several pillars.
Source
Yndigegn T, et al. N Engl J Med. 2024;390(15):1372-81.doi 10.1056/NEJMoa2401479

Discussion & critique

Open-label with lower-than-expected event rates in a well-revascularised population. First modern RCT to challenge routine beta-blockade after MI with preserved EF and, with REBOOT, shifting guidelines.

Discussed in podcasts